Related Experiment Video
Updated: Jun 28, 2026
06:38
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Experimental therapy for advanced renal cell carcinoma
Thomas E Hutson1, Robert A Figlin
1Baylor Sammons Cancer Center, Genitourinary Oncology Program, Texas Oncology, PA, Dallas, Texas 75246, USA. thomas.hutson@usoncology.com
Expert Opinion on Investigational Drugs
|October 17, 2008
Summary
Novel experimental agents show promise for treating advanced renal cell carcinoma (RCC). Ongoing clinical trials are crucial for defining the role of these new therapies in metastatic RCC.
Area of Science:
- Oncology
- Nephrology
- Translational Medicine
Background:
- Metastatic renal cell carcinoma (RCC) treatment has evolved significantly with targeted therapies.
- Agents like sunitinib, sorafenib, and bevacizumab have improved outcomes by targeting VEGF pathways.
- Research is exploring novel agents and pathways for advanced RCC therapy.
Purpose of the Study:
- To provide a comprehensive review of experimental agents under development for advanced RCC.
- To highlight emerging therapies targeting novel pathways in RCC treatment.
Main Methods:
- Literature review of abstracts from recent scientific meetings.
- Systematic search of Medline/PubMed for published manuscripts on experimental RCC therapies.
Main Results:
- Several experimental agents demonstrate significant antitumor activity in preliminary studies.
- These agents show potential for treating advanced and metastatic RCC.
Conclusions:
- Emerging therapies hold promise for advanced renal cell carcinoma (RCC) treatment.
- Further clinical trials are essential to establish the efficacy and role of these novel agents in metastatic RCC management.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...